iCAD (NASDAQ:ICAD - Get Free Report) was downgraded by investment analysts at StockNews.com from a "hold" rating to a "sell" rating in a report issued on Friday.
iCAD Stock Down 4.4 %
NASDAQ:ICAD traded down $0.14 during trading hours on Friday, reaching $3.06. The company had a trading volume of 457,173 shares, compared to its average volume of 664,045. The firm has a market capitalization of $81.21 million, a PE ratio of -23.54 and a beta of 1.47. The stock has a 50-day moving average of $2.03 and a two-hundred day moving average of $1.75. iCAD has a one year low of $1.18 and a one year high of $3.78.
Institutional Inflows and Outflows
A number of institutional investors have recently modified their holdings of the company. Essex LLC bought a new stake in shares of iCAD during the third quarter valued at approximately $216,000. Summit Trail Advisors LLC acquired a new position in iCAD during the 4th quarter worth $214,000. Finally, waypoint wealth counsel boosted its position in iCAD by 44.0% in the 4th quarter. waypoint wealth counsel now owns 14,400 shares of the technology company's stock valued at $26,000 after buying an additional 4,400 shares during the last quarter. Institutional investors own 24.61% of the company's stock.
About iCAD
(
Get Free Report)
iCAD, Inc engages in the provision of cancer detection and therapy solutions in the United States. It operates through two segments, Detection and Therapy. The company provides ProFound AI for digital breast tomosynthesis and 2D mammography; PowerLook, a density assessment solution; and ProFound Risk, a breast cancer risk analysis.
Featured Stories
Before you consider iCAD, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and iCAD wasn't on the list.
While iCAD currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
